

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JBM (Healthcare) Limited

健倍苗苗 (保健) 有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2161)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of JBM (Healthcare) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Xu Hong Xi (“**Dr. Xu**”) has been appointed as a non-executive Director with effect from 2 October 2025.

The biographical details of Dr. Xu are set out as follows:

Dr. Xu, aged 64, has been appointed as a non-executive Director with effect from 2 October 2025. Dr. Xu is currently the distinguished professor of Shanghai University of Traditional Chinese Medicine, the honorary dean of the School of Pharmacy, and the head of the Engineering Research Center of Shanghai Colleges for Traditional Chinese Medicine New Drug Discovery. Dr. Xu is honoured as a “State Specially Recruited Expert”, the first batch “Shanghai Distinguished Expert” and concurrently serves as the secretary-general of Chinese Medicine Academic Disciplinary Assessment team of the State Council Academic Degrees Committee, a member of Chinese Medicine Professional Education Steering Committee under Ministry of Education, a member of Chinese Pharmacopoeia Commission, the chairman of the Belt and Road Alliance for Traditional Chinese Medicine, the honorary chairman of the Chinese Medicine Experimental Pharmacology Branch of China Association of Chinese Medicine, the honorary chairman of the Chinese Medicine Professional Committee of the Shanghai Pharmaceutical Association, the co-chairman of the International Conference on the Modernization of Chinese Medicine. Dr. Xu successively served as the scientific officer of the Chinese Medicine Research Centre at The Chinese University of Hong Kong, the deputy general manager and senior medical advisor of Hutchison Whampoa (China) Limited, a director and the R&D director of Shanghai Hutchison Pharmaceuticals Limited, and the deputy director of the Hong Kong Jockey Club Institute of Chinese Medicine. Dr. Xu is currently an independent non-executive director of Beijing Tong Ren Tang Chinese Medicine Company Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 3613).

Dr. Xu graduated from Shanghai University of Traditional Chinese Medicine in 1983 and 1989 with a bachelor's degree and master's degree, respectively, and obtained his Ph.D. degree in Pharmaceutical Sciences in 1994 from Toyama Medical and Pharmaceutical University in Japan, and conducted postdoctoral research at the National University of Singapore and Dalhousie University in Canada between 1994 and 1998.

Save as disclosed above and as at the date of this announcement, Dr. Xu (i) has not previously held and does not hold any other positions with the Group; (ii) did not hold any other directorships in any public companies the securities of which are listed in Hong Kong or overseas in the last three years; and (iii) did not have any other major appointments and professional qualifications.

As at the date of this announcement, Dr. Xu does not have any relationships with any other Directors, senior management or substantial or controlling shareholders of the Company, and he does not have any interests in the shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Pursuant to an appointment letter entered into between Dr. Xu and the Company, Dr. Xu is entitled to receive a remuneration of HK\$220,000.00 per annum (subject to review by the remuneration committee of the Board from time to time). He is also entitled to (i) receive a discretionary bonus as the Board may determine in its absolute discretion from time to time; and (ii) participate at the discretion of the Board in the Company's share award scheme adopted on 18 January 2021 and amended on 21 September 2023 or other share options, share award or incentive scheme of the Company on such terms as may be determined by the Board from time to time. Such remuneration is determined by reference to factors including his background, qualifications, experiences, duties and responsibilities within the Group, and the prevailing market conditions.

According to the appointment letter entered into between Dr. Xu and the Company, Dr. Xu shall be appointed for an initial term commencing on the date of appointment and expiring on 30 September 2028. According to the Articles of Association of the Company, Dr. Xu will hold office until the annual general meeting of the Company in 2026 (the “**2026 AGM**”), and shall then be eligible for re-election at the 2026 AGM. Thereafter, he will be subject to retirement by rotation at an annual general meeting of the Company in accordance with the Articles of Association of the Company.

Save as disclosed above, there are no other matters concerning the appointment of Dr. Xu that need to be brought to the attention of the shareholders of the Company and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to express its warmest welcome to Dr. Xu on his appointment.

By Order of the Board
JBM (Healthcare) Limited
YU Chun Kau
Company Secretary

Hong Kong, 30 September 2025

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman), Mr. Yim Chun Leung and Dr. Cheng Celine Heung Kwan as executive Directors, Mr. Yeung Kwok Chun, Harry as non-executive Director, and Mr. Chan Kam Chiu, Simon, Mr. Luk Ting Lung, Alan and Mr. Lau Shut Lee, Tony as independent non-executive Directors.